SERUM MACROPHAGE MIGRATION INHIBITORY FACTOR LEVEL IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND ITS RELATION TO DISEASE ACTIVITY
European Journal of Molecular & Clinical Medicine,
2021, Volume 8, Issue 2, Pages 2438-2445
AbstractBackground: Ankylosing Spondylitis (AS) is a chronic inflammatory form of arthritis that predominantly affects the axial joints and has a global prevalence of 1%. It is the most commonly occurring form of spondyloarthropathy. Macrophage migration inhibitory factor (MIF) is a potent pro-inflammatory cytokine implicated in several diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic vasculitis and ankylosing spondylitis
Objective: To determine the serum levels of macrophage migration inhibitory factor in ankylosing spondylitis patients and to find out its possible correlation with disease activity. Patients and methods: This study was a case-control study conducted on 52 subjects (21 Ankylosing Spondylitis “AS”), and 21 healthy controls; to determine the serum levels of macrophage migration inhibitory factor (MIF) in ankylosing spondylitis patients and tofind out its possible correlation with disease activity.
Results: Our results showed statistically significant difference between the studied groups regarding MIF (significantly higher in AS group).
Conclusion: MIF appears to have the unique ability to drive inflammation and could playan important role in the pathogenesis of AS.
- Article View: 47
- PDF Download: 19